# An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome

> **NCT05011851** · PHASE2 · COMPLETED · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 17 (actual)

## Conditions studied

- Angelman Syndrome

## Interventions

- **DRUG:** NNZ-2591

## Key facts

- **NCT ID:** NCT05011851
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-12
- **Primary completion:** 2024-05-13
- **Final completion:** 2024-07-16
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011851, "An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05011851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*